3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
6
Uterine Cervical Neoplasms
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Multiple Myeloma
2
Adenomatous Polyposis Coli
2
Uterine Neoplasms
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Smoldering Multiple Myeloma
1
Sezary Syndrome
1
Radiodermatitis
1
Prostate Cancer Metastatic Castration Resistant
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pain
1
Neoplasms
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Monoclonal Gammopathy of Undetermined Significance
1
Lymphoma, T-Cell, Cutaneous
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Head and Neck Neoplasms
1
Gastritis, Atrophic
1
Fatigue
1
Endometrial Neoplasms
1
Communicable Diseases
1
Colorectal Neoplasms
1
Interventions
Morphine
6
Analgesia
6
nabiximols
3
Pregabalin
3
Oxycodone
3
Fentanyl
3
ziconotide
2
Surveys and Questionnaires
2
Saline Solution
2
Radiofrequency Ablation
2
Methadone
2
Lidocaine
2
Ketamine
2
Ibandronic Acid
2
Gemcitabine
2
Duloxetine Hydrochloride
2
Docetaxel
2
Botulinum Toxins, Type A
2
trimebutine 3-thiocarbamoylbenzenesulfonate
1
tanezumab
1
tandutinib
1
siltuximab
1
resiniferatoxin
1
incobotulinumtoxinA
1
imisopasem manganese
1
fulranumab
1
erenumab
1
cyclobenzaprine
1
caffeine, sodium benzoate drug combination
1
Therapeutics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pain
×
Curcumin
×
Clear all
NCT02556632
2017-11-06
Curcumin-II
University of Rochester
Phase 2
Completed
191 enrolled
23 charts